Background: A novel 13-valent pneumococcal conjugate vaccine (PCV13-TT) has been widely used in China since its licensure in 2019. The prelicensure pivotal clinical study (PCV13-002) showed strong immune responses against 13 serotypes with PCV13-TT using two different 3P + 1 schedules starting at either 2 (PCV13-2M) or 3 months (PCV13-3M) of age.
Methods: To assess antibody persistence, healthy Chinese toddlers from PCV13-002 were recalled for blood collection at 1 and 2 years post booster dose. Antibody persistence was evaluated using ELISA and OPA assay methods to measure serotype-specific antibodies.
Results: Similar immune responses were noted for both PCV13-3M and PCV13-2M groups. IgG GMCs remained high (ranging from 0.39 to 4.68 μg/mL) through 2 years post 4 doses of PCV13-TT, with IgG positive rates against most serotypes maintained at ≥90%. Both OPA GMTs and OPA positive rates remained high compared to levels observed at 1 month post booster.
Conclusion: After complete dosing schedule of PCV13-TT starting from either 2 months or 3 months, the antibody level declined through 1 year and 2 years post booster dose, while still remained at relatively high levels at the two timepoints as compared to those observed at 1 month post booster dose for the majority of serotypes.
Clinical Trial Registration: CTR20182353.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2025.126815 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes.
J Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFWhat is the value of testing for tick-borne diseases in cattle in endemic areas? A case study of bovine anaplasmosis.
PLoS One
March 2025
Instituto de Investigación en Zoonosis (CIZ), Universidad Central del Ecuador, Quito, Ecuador.
Anaplasmosis is a tick-borne disease (TBDs) caused by Anaplasma spp. In areas where TBDs are endemic, it is crucial to consider the animals' immunological status in relation to these diseases. The true prevalence of bovine anaplasmosis, the percentage of animals with protective antibodies against this TBD, and the diagnostic characteristics of three tests (multiplex polymerase chain reaction (mPCR), competitive-inhibition enzyme-linked immunosorbent assay (cELISA), and blood smear (BS)) were estimated using a Bayesian approach.
View Article and Find Full Text PDFA novel dominant-negative variant of IRF8 in a mother and son: Clinical, phenotypic and biological characteristics.
J Allergy Clin Immunol
March 2025
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn. Electronic address:
Background: The few reported patients with pathogenic IRF8 variants have manifested 2 distinct phenotypes: (1) an autosomal recessive severe immunodeficiency with significant neutrophilia and absence of or significant decrease in monocytes and dendritic cells and (2) a dominant-negative form with only a decrease in conventional type 2 dendritic cells (cDC2s) and susceptibility to mycobacterial disease.
Objectives: Genetic testing of a child with persistent EBV viremia identified a novel IRF8 variant: c.1279dupT (p.
Heterologous prime-boost immunization of two-component vaccine candidate PWDVax protected pigs against F18 enterotoxigenic post-weaning diarrhea.
Infect Immun
March 2025
Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.
Post-weaning diarrhea (PWD) is associated predominantly with enterotoxigenic (ETEC) and continuously causes significant economic losses to swine producers worldwide. Currently, there are no effective countermeasures against this significant swine disease. Challenges persist in developing vaccines against PWD since ETEC strains produce heterogeneous virulence factors, including F4 (K88) and F18 fimbria and heat-labile toxin (LT), heat-stable toxin type I (STa), heat-stable toxin II (STb), and Shiga toxin type 2e (Stx2e, also causes edema disease).
View Article and Find Full Text PDFTherapeutic perspectives for recurrent or metastatic head and neck squamous cell carcinoma.
Curr Opin Oncol
March 2025
Centre Léon Bérard, Lyon, France.
Purpose Of Review: Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains a significant therapeutic challenge due to its biological complexity and clinical heterogeneity. This review addresses the relevance of exploring novel therapeutic approaches, particularly in light of recent advances and the persistent unmet needs in patient outcomes.
Recent Findings: Recent phase II and III clinical trials have highlighted promising strategies, including combinations of immunotherapy with targeted therapies, antibody-drug conjugates (ADCs), HPV vaccines, dual immunotherapy approaches, and therapies targeting the tumor microenvironment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!